Later, when VNP20009 synergic combined with an anti-angiogenesis inhibitor, endostatin which has no significant anti-tumor effect alone, this strategy significantly enhances therapeutic effects on tumor progressions and normalizes vessels [260]. This evidence concerns the gene COL18A1 and neoplasm.